News
Tapering TNF inhibitors is safe and maintains low disease activity for 2 years in psoriatic arthritis and axial ...
Lower muscle volume and more fat stored in the muscle are seen linked to higher risk for disease and comorbidities.
7d
Flow Space on MSNPsoriatic Arthritis Is Most Commonly Diagnosed in This Age Group—& We’re Honestly SurprisedWe often imagine arthritis as a condition exclusive to people well into their golden years, yet data shows psoriatic ...
Objectives The reproductive health of men with inflammatory joint disease (IJD) has been a topic of debate in recent years, ...
Dealing with the itchy, scaly patches that come with psoriasis is difficult enough. But having psoriasis puts you at risk of ...
Among patients with PsA, MetS was independently associated with a D2T phenotype, even when accounting for fibromyalgia and disease activity.
12d
Everyday Health on MSNHow to Manage the Heart Disease Risk of Psoriatic ArthritisUnderstand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.
With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.
Health experts reveal the impact of the inflammatory skin condition on joints, and highlight symptoms and management tips ...
20h
Flow Space on MSNStacy London on What She Wished She Knew Before Getting Her Psoriatic Arthritis DiagnosisBefore Stacy London received her psoriatic arthritis diagnosis in her 30s, she didn't have answers for why her hardcore workouts left her feeling ill or why fatigue interfered with her fast-paced life ...
In this video, Philip J. Mease, MD, discusses the potential for the development of a T-cell engaging antibody.
The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results